Ionis cuts revenue forecast for key drug by 50%, shares drop sharply.

Ionis Pharmaceuticals sharply reduced its revenue guidance for one of its main drugs due to weak sales, causing its stock to fall significantly in premarket trading. This revenue cut overshadows the company's otherwise solid earnings report. The lowered outlook raises concerns about the drug's market performance and could impact investor confidence going forward.

Ionis Pharmaceuticals' stock price dropped sharply by 20.85% to USD 31.20 on Pluang as of Nov 09, 2026 20:11 WIB, reflecting significant market reaction to the company's revenue forecast cut. The stock's market cap stands at $6.55 billion with a trading volume of 2,911,470 shares, indicating active investor engagement. This price movement aligns with the news of the revenue guidance reduction for a key drug, impacting investor sentiment.